Clinical Trials Logo

Infections clinical trials

View clinical trials related to Infections.

Filter by:

NCT ID: NCT06395675 Not yet recruiting - Clinical trials for Chlamydia Trachomatis Infection

Clinical Evaluation of the ID NOW™ CT/NG Test

Start date: July 9, 2024
Phase: N/A
Study type: Interventional

The objective of this study is to determine the performance of the ID NOW™ CT/NG test in male urine, female urine, and self-collected vaginal swabs when tested by intended users (i.e., untrained operators). ID NOW™ CT/NG test results will be compared to results from up to three (3) FDA cleared CT/NG nucleic acid amplification tests (NAATs) for each sample type.

NCT ID: NCT06395636 Not yet recruiting - Appendicitis Clinical Trials

Early Detection of Infection Using the Fitbit in Pediatric Surgical Patients

i-DETECT
Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The purpose of this study is to analyze Fitbit data to predict infection after surgery for complicated appendicitis and the effect this prediction has on clinician decision making.

NCT ID: NCT06395324 Not yet recruiting - Clinical trials for Microbial Colonization

Fiber Effectively Educates & Directs the Microbiome Study

FEEDMe
Start date: May 15, 2024
Phase: N/A
Study type: Interventional

The FEEDMe Study is a single-group, open label pilot study exploring how diverse, commercially available foods rich in arabinose influence the gut microbiome in adults from diverse populations.

NCT ID: NCT06395116 Active, not recruiting - Clinical trials for Inflammatory Response

Microbial Adhesion and Biofilm Formation on Denture Base Materials

Start date: January 20, 2023
Phase:
Study type: Observational

Polymethylmethacrylate (PMMA) has been the material of choice for fabricating complete dentures for more than 80 years now.(1,2) As a material it is easy to handle and can be easily repaired and polished. PMMA while being a low-cost material has good esthetics. Some disadvantages of PMMA as a material are surface roughness and porosities which lead to staining, plaque accumulation and bacterial adhesion over time. Among the various factors that can influence microbial attachment to surfaces, surface roughness, hydrophilicity and free surface energy of PMMA are most important. Carboxylate and methyl ester groups found in PMMA make it a very hydrophilic material with a large amount of free surface energy. Despite the influence of the chemical composition, processing methods play the most important role in developing surface roughness.

NCT ID: NCT06394518 Completed - Clinical trials for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Phase 1, Single-Dose and Multiple-Dose Continuous Intravenous Infusions of TNP-2092 for Injection in Healthy Chinese Participants

Start date: July 7, 2022
Phase: Phase 1
Study type: Interventional

This is a phase 1, single-center, randomized, double-blind, placebo-controlled, dose-escalation clinical trial of single and multiple intravenous doses of TNP-2092 for injection in healthy Chinese participants.

NCT ID: NCT06393387 Not yet recruiting - HIV Infections Clinical Trials

Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States

Start date: June 1, 2024
Phase:
Study type: Observational

This real-world retrospective study describes the clinical efficacy of 2DR (DOVATO® (DTG/3TC)) versus 3DR (BIKTARVY® (BIC/F/TAF)) in PWH, including those with at least 2 social determinants of health indicators, across a multi clinic infectious disease organization in the Southeast United States

NCT ID: NCT06392581 Recruiting - Clinical trials for Acute Lymphoblastic Leukemia

Observational Study on Invasive Fungal Infection Incidence in Ph-neg Acute Lymphoblastic Leukemia Patients

ALL-IFI
Start date: April 14, 2022
Phase:
Study type: Observational

Primary objective To document the occurrence of fungal infections during the early stages of chemotherapy (from onset to TP2, i.e., week 16) in adult Ph-neg ALL patients Secondary objectives - To document the occurrence of IFI in relation to antifungal prophylaxis adopted - To document the occurrence of IFI in relation to the age of the patients - Document the occurrence of IFI in relation to the duration of neutropenia - Document the occurrence of IFI in relation to the type of steroid treatment adopted (dexamethasone yes vs no) - Document any delays in the initiation of consolidation chemotherapy in LLA patients with IFI - Document the outcome of patients with ALL with IFI Study design The study is prospective and observational, multicenter, real-life study involving 26 centers afferent to the SEIFEM group. All Ph-neg ALL patients aged 18 years or older treated with intensive chemotherapy starting from 01.06.22 for the duration of 18 months (+12 months follow-up) will be enrolled. The diagnosis of IFI will be defined according to EORTC 2019 criteria. Clinical information will be collected in paper CRFs, compiled anonymously. The incidence of IFI and pulmonary aspergillosis during induction chemotherapy will be related to the following variables: - Age - Sex - Type of AF prophylaxis performed - LLA risk classification according to ESMO 2016 criteria - Dose of dexamethasone administered - Duration of neutropenia - Hematologic and molecular response

NCT ID: NCT06392568 Recruiting - Critical Illness Clinical Trials

Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units

NOSOREA3
Start date: April 1, 2024
Phase:
Study type: Observational

Investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus.

NCT ID: NCT06392451 Not yet recruiting - Clinical trials for Coronavirus Disease 2019

LIAISON NES Influenza (FLU) A/B, Respiratory Syncytial Virus (RSV), & Coronavirus Disease 2019 (COVID-19) in Symptomatic Patients in Australia

Start date: May 6, 2024
Phase: N/A
Study type: Interventional

To establish the relative accuracy of the LIAISON® NES Flu A/B, RSV & COVID-19 assay for viral nucleic acid targets from professionally collected or patient self-collected dry nasal (NS) swabs and to establish the relative accuracy of the LIAISON PLEX® RSP Flex assay from NS and nasopharyngeal swabs (NPS) in applicable transport media from human patients exhibiting clinical signs and symptoms of a respiratory tract infection.

NCT ID: NCT06392282 Active, not recruiting - Clinical trials for Urinary Tract Infections

MV-140 Efficacy in Recurrent Urinary Tract Infections in a Cohort of Portuguese Adult Patients

Start date: June 1, 2023
Phase:
Study type: Observational [Patient Registry]

We will access the efficacy of MV-140 immunotherapy in the prevention of recurrent urinary tract infections in a cohort of Portuguese patients.